Mirae Asset Global Investments Co. Ltd. Purchases New Holdings in Becton, Dickinson and Company $BDX

Mirae Asset Global Investments Co. Ltd. purchased a new position in Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 80,548 shares of the medical instruments supplier’s stock, valued at approximately $14,418,000.

A number of other large investors have also modified their holdings of the stock. Maryland Capital Advisors Inc. increased its holdings in Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 139 shares during the period. Trifecta Capital Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 59.0% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 62 shares during the period. Meeder Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the period. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Becton, Dickinson and Company during the second quarter worth about $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,907 shares of company stock valued at $1,269,128 over the last three months. 0.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Wolfe Research assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, October 20th. They set an “outperform” rating for the company. Barclays began coverage on shares of Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective on the stock. Finally, Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $185.07.

Becton, Dickinson and Company Trading Down 0.4%

NYSE:BDX opened at $197.88 on Wednesday. The stock has a 50-day simple moving average of $186.86 and a 200-day simple moving average of $170.20. The stock has a market cap of $54.52 billion, a P/E ratio of 59.60, a P/E/G ratio of 13.39 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $200.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the business posted $3.68 EPS. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.